DOTA-mono-NHS-tris(t-Bu ester)?(B-270)
$400.00
CAS No.: 819869-77-7
Catalog No.: HKP0104
Purity: 95%
MF: C32H55N5O10
MW: 669.817
Storage: 2-8 degree Celsius
SMILES: O=C1N(C(CC1)=O)OC(CN1CCN(CCN(CCN(CC1)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)=O
Catalog No.: HKP0104
Purity: 95%
MF: C32H55N5O10
MW: 669.817
Storage: 2-8 degree Celsius
SMILES: O=C1N(C(CC1)=O)OC(CN1CCN(CCN(CCN(CC1)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)CC(=O)OC(C)(C)C)=O
CAS No.: 819869-77-7; DOTA-mono-NHS-tris(t-Bu ester)?(B-270). PROPERTIES: DOTA-mono-NHS-tris(t-Bu ester) is a chelating agent derivative with molecular formula C33H51N3O12. This white to off-white powder has a molecular weight of approximately 701.8 g/mol. It exhibits excellent solubility in dimethylformamide and other common coupling solvents. The compound is sensitive to hydrolysis and must be stored at -20 C in desiccated conditions. Safety precautions include wearing chemical-resistant goggles and avoiding inhalation. The NHS ester functional group renders it reactive toward primary amines. APPLICATIONS: In bioconjugation chemistry, DOTA-mono-NHS-tris(t-Bu ester) serves as a chelator for radiometal labeling of biomolecules, as documented in Bioconjugate Chemistry. Its application in developing PET imaging probes for cancer detection is reported in Journal of Nuclear Medicine. In immunoconjugate research, the reagent enables creation of radiolabeled antibodies for targeted radionuclide therapy, with findings published in Nature Reviews Cancer. Additionally, it has applications in developing magnetic resonance imaging contrast agents through Gd(III) complexation, as described in Contrast Media & Molecular Imaging.
Reviews
Write Your Own Review